First-Line Treatment of ALK-Positive NSCLC

Abstract

Non-small cell lung cancer (NSCLC) patients with rearrangements in the anaplastic lymphocyte kinase (ALK) gene are highly sensitive to ALK tyrosine kinase inhibitors (TKIs) like alectinib. Here, the case of a 77-year-old male patient with newly diagnosed metastatic ALK-positive NSCLC treated with alectinib has been discussed. The patient achieved a durable (>18 months) complete response and demonstrated excellent clinical tolerance to alectinib.

Keywords

• treatment algorithm
• alectinib
• alk rearrangements
• nsclc